Enrique Grande, Director of the Medical Oncology Department at Quirónsalud, and Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
” Real-world neoadjuvant RC48 (disitamab vedotin) + PD-1 in localized MIBC (n=25):
- pCR 48%
- Pathologic downstaging 88%
- 12-month DFS 91.5%, OS 100%
- Responses enriched in HER2 3+ tumors
Small retrospective cohort, but another signal that ADC + IO may become a relevant option in HER2-expressing MIBC. ”
Title: Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study
Authors: Xuanjun Guo, Shuoyu Wang, Yechi Ma, Yicong Du, Yuke Chen, Qian Wang, Kaiwei Yang, Qi Tang, Yu Fan, Han Hao, Zhisong He, Yanqing Gong, Cuijian Zhang
Read the Full Article.
More posts featuring Enrique Grande.